Upsher-Smith Laboratories announced the launch of Tosymra™ (sumatriptan) Nasal Spray, 10 mg for the acute treatment of migraine with or without aura in adults. Tosymra is a fast-acting, easy-to-use acute migraine treatment option that delivers the efficacy of an injectable in a convenient nasal spray.
Tosymra, which was approved by the U.S. Food and Drug Administration in early 2019, was recently acquired by Upsher-Smith from Dr. Reddy's Laboratories.
"We're excited to launch Tosymra, the third product in Upsher-Smith's growing migraine portfolio, which includes Qudexy® XR and Zembrace® SymTouch®," said Rusty Field, President and CEO, Upsher-Smith. "Many patients face challenges during migraine attacks that make available acute treatment options inadequate. Tosymra Nasal Spray offers an alternative for patients whose symptoms interfere with taking oral medication or who may be dissatisfied with their current treatment regimen."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Tosymra, which utilizes Intravail® technology, efficiently delivers sumatriptan intranasally and achieves median peak plasma concentration five minutes faster than injectable sumatriptan, 4 mg and 6 mg. Additionally, in the two hours following administration, a 10-mg dose of Tosymra demonstrated a markedly increased rate and extent of sumatriptan absorption when compared with Imitrex® 20-mg nasal spray.
More than 36 million patients suffer from migraines and surveys have shown that a majority are willing to try other acute treatment options. Patients currently using oral treatment options may face challenges including nausea and gastroparesis or vomiting which may delay or limit oral medication absorption.